Materialise (MTLS) Q3 2025 earnings summary

Executive summary

• Q3 2025 consolidated revenue was €66.3 million, down 3.5% year-over-year but up over 2% sequentially from Q2 2025.

• The Medical segment achieved double-digit revenue growth, setting a record, while Manufacturing and Software segments faced macroeconomic headwinds.

• Net profit for Q3 2025 was €1.85 million, or €0.03 per diluted share.

• Strategic progress included the acquisition of FEops, expansion of cardiac planning solutions, and new product releases in trauma and AM software.

Financial highlights

• Gross profit margin for Q3 2025 was 56.8%, with gross profit of €37.7 million.

• Adjusted EBIT was €2.92 million (4.4% margin), down from €4.41 million in Q3 2024.

• Adjusted EBITDA for Q3 2025 was €8.43 million (12.7% margin), down from €9.90 million in Q3 2024.

• Net cash position increased to €67.7 million, driven by strong free cash flow.

• Cash and cash equivalents at quarter-end were €132 million; gross debt rose to €64.3 million.

Outlook and guidance

• Full-year 2025 revenue expected between €265 million and €280 million; adjusted EBIT guidance maintained at €6–10 million.

• Management remains confident in business resilience and future growth opportunities despite macroeconomic and geopolitical headwinds.